SA
Create Free Alerts
Biohaven Ltd.BHVNNYSE
Loading
OverviewIntelligenceChartsNews

Latest News

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
prnewswire.com

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now fully enrolled; topline data expected in 2H 2026. Taldefgrobep is a novel inhibitor of the myostatin-activin signaling pathway, which directly targets both fat and muscle, offering the potential to achieve high-quality weight loss in people living with overweight and obesity.

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
prnewswire.com

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results

Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDETM) and Targeted Removal of Aberrant Protein (TRAPTM) extracellular protein degradation for immunological diseases, Kv7 ion channel modulation for epilepsy; and myostatin-activin pathway targeting obesity: Inflammation and Immunology: Graves' Disease: First-in-patient clinical experience with IgG MoDE degrader BHV-1300 resulted in complete suppression of disease-causing TSH receptor-stimulating antibodies, normalization of previously elevated thyroid hormones within weeks after dosing a patient with Graves' disease. BHV-1300 has shown the potential for best-in-class reductions of IgG, with maximum reductions of up to an 87% decrease from baseline within weeks of dosing in a study conducted in healthy volunteers.

Here Are Friday’s Top Wall Street Analyst Research Calls: Amazon.com, Caterpillar, Estee Lauder, JPMorgan, Norfolk Southern, Roku, Snap, Vistra, and More
247wallst.com

Here Are Friday’s Top Wall Street Analyst Research Calls: Amazon.com, Caterpillar, Estee Lauder, JPMorgan, Norfolk Southern, Roku, Snap, Vistra, and More

Pre-Market Stock Futures: Futures are trading higher as we prepare to wrap up one of the worst trading weeks in some time. The song remains the same as the rotation out of the tech trade continues to gain strength. Toss in the weakness in cryptocurrencies, along with a renewed skepticism towards the asset, and the... Here Are Friday's Top Wall Street Analyst Research Calls: Amazon.com, Caterpillar, Estee Lauder, JPMorgan, Norfolk Southern, Roku, Snap, Vistra, and More.

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
prnewswire.com

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary MoDE™ and next-generation, highly selective TRAP™ degraders exclusively licensed from Yale University. Early clinical experience in patients demonstrates rapid removal of circulating disease-causing proteins, resulting in robust clinical improvement with a well-tolerated profile to date: IgA Nephropathy (IgAN) Program: First dosing of BHV-1400 TRAP degrader in IgAN patients achieved early observations of both biomarker and clinical responses including: selective lowering of only the disease-causing galactose-deficient IgA1 (Gd-IgA1) while sparing off-target effects on healthy antibodies (IgA, IgM, IgE, IgG), resolution of blood in the urine (hematuria), deep reductions in proteinuria, and improvement in fatigue and kidney function (eGFR) within weeks.

Cautiously Bullish After Biohaven's Cash Runway And Dilution Risk Rise
seekingalpha.com

Cautiously Bullish After Biohaven's Cash Runway And Dilution Risk Rise

BHVN's investment case definitely weakened after Opakalim's Phase 2 MDD miss. This also means they'll discontinue their psychiatric development. BHVN's pipeline remains diverse, but key assets like Opakalim for depression and Taldefgrobep alfa for SMA missed primary endpoints. Current cash runway is approximately 3.1 quarters, heightening urgency for successful near-term clinical milestones and FDA approvals.

ARS Investment Partners LLC Sells 85,577 Shares of Biohaven Ltd. $BHVN
defenseworld.net

ARS Investment Partners LLC Sells 85,577 Shares of Biohaven Ltd. $BHVN

ARS Investment Partners LLC decreased its stake in shares of Biohaven Ltd. (NYSE: BHVN) by 7.2% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,102,549 shares of the company's stock after selling 85,577 shares during the quarter. Biohaven comprises about

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance